| First Author | de Vos S | Year | 1998 |
| Journal | Leukemia | Volume | 12 |
| Issue | 3 | Pages | 401-5 |
| PubMed ID | 9529135 | Mgi Jnum | J:46617 |
| Mgi Id | MGI:1201695 | Doi | 10.1038/sj.leu.2400940 |
| Citation | de Vos S, et al. (1998) Immunotherapy against murine leukemia. Leukemia 12(3):401-5 |
| abstractText | The central hypothesis underlying specific anti-leukemia immunotherapy is that leukemic cells express antigenic determinants not expressed on their counterpart normal adult cells. We have developed a murine myeloid leukemia/tumor immunization model using the low-immunogenic WEHI3 leukemia in syngeneic mice. Mice preimmunized with irradiated, transduced IL-7-producing WEHI3 cells showed systemic protection and rejection of a lethal dose of intravenously (i.v.) injected parental WEHI3 cells (5 x 10(4)) with 40% long-term survival. When vaccinated with a mixture of parental WEHI3 cells and IL-2-producing NIH-3T3 fibroblasts (5 x 10(5)), 60% survival was observed. Vaccination with murine granulocyte-macrophage colony-stimulating factor (GM-CSF)- producing WEHI3 cells resulted in only 20% survival of i.v. challenged mice, and the additional combination of IL-2- and IL-7-producing vaccine did not reveal any additive or synergistic effects. Immunizing mice with a pre-established leukemia burden (injected with 5 x 10(4) WEHI3 cells, i.v., 3 days prior to immunization) did not cure or result in a prolongation of survival, indicating that improved methods of immunization are needed. Taken together, we have identified IL-7 and IL- 2 as effective cytokines in our leukemia/vaccination model with only marginal activity by GM-CSF. |
